drugset / Trial / NCT00245336

Study of Recombinant Human Thrombin for Bleeding During Surgery

NCT00245336

Phase 3 Completed 401 enrolled ZymoGenetics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether recombinant human Thrombin (rhThrombin) is effective in stopping bleeding during surgery, in comparison with bovine thrombin.

Timeline

Start
2005-10
Primary completion
2006-06
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bovine Thrombin Protein / enzyme biologic 1000 unknown Topical
Subject rhThrombin Protein / enzyme biologic 1000 unknown Topical

Indications

No indication recorded.